ibSium Can Help to Manage Symptoms of Gastrointestinal Disorders

23 Mar 2017 --- Lesaffre Human Care has announced that findings of a recent meta-analysis support claims that ibSium benefits gastrointestinal disorders. The research reveals that subjects who consumed ibSium felt 12.3% less pain/gastrointestinal discomfort than when consuming a placebo.

This result is above the 10% minimum threshold considered by the scientific experts as clinically relevant, and the new paper strengthens previous conclusions on the ingredient’s capacity to alleviate gastrointestinal disorders’ symptoms. 

The individual patient data meta-analysis was performed on the data collected during two randomized clinical trials, studying the effect of a daily supplementation of ibSium (Saccharomyces cerevisiae CNCM I-3856) in volunteers suffering from Irritable Bowel Syndrome (IBS). 

IBS subjects are generally considered as a suitable study group to evaluate gastrointestinal discomfort and substantiate claims intended for the general population. Lesaffre Human Care therefore decided to perform clinical studies on IBS subjects to demonstrate ibSium’s efficacy on abdominal pain & discomfort, bloating and constipation. 

Researchers concluded that “this meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI [gastrointestinal] symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations.”

Statistical analysis was conducted on the scores for abdominal pain/discomfort and bloating and on the measurement of bowel movements (stool frequency and consistency) in 579 healthy volunteers suffering from IBS according to Rome III criteria.

In the IBS-C subpopulation, volunteers in the active group felt 12.3% less bloated compared to the placebo group. In this subpopulation, stool consistency in the ibSium group was significantly higher and classified as normal compared to the placebo group (p=0.0003) at the end of the supplementation period. 

These results confirm the beneficial effect of ibSium previously observed in both clinical trials. 

“Beyond the scientifically vetted proof of efficacy it provides, this new official publication is a recognition of the company’s long-term investment in providing strong scientific and clinical data to substantiate the health benefits of its patented ingredient: ibSium”, states Elodie Ruffin, Product Manager for Probiotics at Lesaffre Human Care. 

“Approximately a third of the world’s population (roughly 2.4 billion people) is complaining about some gut-related symptoms.”

“In this context, it is our responsibility, as one of the major companies in the human care segment, to contribute to improving the quality of life of these people by providing a natural alternative proven to help ease gastrointestinal symptoms,” she explains. 

Lesaffre Human Care say that ibSium can be considered as an innovative strategy to improve the quality of life in people suffering from digestive disorders, such as IBS subjects. 

Based on the solid scientifical and clinical evidence available, ibSium also benefits from a health claim granted by Health Canada in 2015, and has been approved by consumers through a large-scale study run by prescribing physicians in over 1160 volunteers presenting symptoms of IBS. ibSium has also been proven to be safe, fast-acting (less than 15 days) and well-tolerated, inducing no side-effects or habituation.